Get Premium to unlock powerful stock data
NAS:RARE (USA)  
Ultragenyx Pharmaceutical Inc logo

Ultragenyx Pharmaceutical Inc

$ 60.24 +1.51 (+2.57%) 11:08 PM EST
P/E:
At Loss
P/B:
5.25
Market Cap:
$ 4.21B
Enterprise V:
$ 3.55B
Volume:
306.63K
Avg Vol (2M):
609.57K
Also Trade In:
Volume:
306.63K
Market Cap $:
4.21B
PE Ratio:
At Loss
Avg Vol (2-Month):
609.57K
Enterprise Value $:
3.55B
PB Ratio:
5.25
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Ultragenyx Pharmaceutical Inc
NAICS : 325412 SIC : 2834
60 Leveroni Court, Novato, CA, USA, 94949
Description
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Name Current Vs Industry Vs History
Cash-To-Debt 15.2
Equity-to-Asset 0.58
Debt-to-Equity 0.05
Debt-to-EBITDA -0.09
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.6
Distress
Grey
Safe
Beneish M-Score -2.8
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 69.13
9-Day RSI 66.03
14-Day RSI 60.17
6-1 Month Momentum % -41.2
12-1 Month Momentum % -49.49

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.23
Quick Ratio 4.12
Cash Ratio 3.58
Days Inventory 331.24
Days Sales Outstanding 29.01
Days Payable 405.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.9

Financials (Next Earnings Date:2022-08-02 Est.)

RARE's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:RARE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 331.946
EPS (TTM) ($) -6.87
Beta 1.21
Volatility % 49.37
14-Day RSI 60.17
14-Day ATR ($) 3.413744
20-Day SMA ($) 53.3435
12-1 Month Momentum % -49.49
52-Week Range ($) 45.2 - 104.38
Shares Outstanding (Mil) 69.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ultragenyx Pharmaceutical Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More